Maybe they think you've been ramping too much.
in their defense, looking at it from a lay perspective, this isn't entirely relevant to our core strategy ie cancer(I realise it further reaffirms FTO in a human's overall disease process). And it isn't a new finding per se, as we know zantrene and FTO is linked(twice already independently).
While I agree it further reaffirms the Zantrene and FTO link, from what I can see, diabetes isn't on the cards for any clinical trials. A lot of posters here have been prematurely excited off this paper, but there is still a lot of work to be done before there would be a tangible return, IMO.
with that said, you did say you deemed it as not price sensitive, so I'm not sure how it's ramping.
This from a non scientific POV, Dr T.. I'm happy for you to correct me if you think otherwise.
Ann: Quarterly Activity Report & Appendix 4C, page-23
-
- There are more pages in this discussion • 54 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.70 |
Change
0.090(5.59%) |
Mkt cap ! $289.5M | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.76 | $1.59 | $142.7K | 84.97K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 17175 | $1.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.77 | 6060 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |